access to cancer care

Science is moving at extraordinary speed. We can identify mutations once invisible, develop drugs that destroy proteins previously considered untouchable, and transform diagnoses that once offered little hope. Yet a patient can still wait too long for treatment. A brilliant…

“Tax planning was one major reason for the foundation of Elekta.” Larry Leksell says it with a smile that suggests he enjoys disrupting the mythology people create around founders. Most people expect a grand story of origin. A visionary revelation.…

Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…